AstraZeneca Submits Brilinta To FDA, But Review Could Be Lengthy
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
AstraZeneca's submission of its antiplatelet drug Brilinta (ticagrelor) to FDA, announced Nov. 19, was on time for the firm's projections. Now it has to wait and see if an on-time approval is in the cards
You may also be interested in...
Is TMC's Cangrelor A CHAMPION After All?"Noise On The Line" Confounded Endpoint Data, CEO Says
Inability to pinpoint whether angioplasty patients enrolled in Phase III trials of The Medicines Company’s reversible antithrombotic cangrelor were already having a heart attack when they were randomized into the studies may have confounded endpoints in the failed program, according to CEO Clive Meanwell.
Is TMC's Cangrelor A CHAMPION After All?"Noise On The Line" Confounded Endpoint Data, CEO Says
Inability to pinpoint whether angioplasty patients enrolled in Phase III trials of The Medicines Company’s reversible antithrombotic cangrelor were already having a heart attack when they were randomized into the studies may have confounded endpoints in the failed program, according to CEO Clive Meanwell.
FDA Updates Plavix Label, Leaves Effient With Clear Advantage
FDA expands upon the warning that it discreetly slipped into the anti-clotting drug's labeling in May, with new data that clopidogrel is 50% less effective when given with Prilosec.